Company / PP&E (Net)
Editas Medicine, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.5M
FY2025
5-year range
$3.5M / $17.1M
FY2021-FY2025
Trend
-75.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 8 years, ranging from $4M in FY2025 to $40M in FY2018.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -24.1%.
Declined from $12M to $4M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -39.0%
- 5-Year CAGR
- -24.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -24.1%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 75.6% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.5M | -75.6% |
| FY2024 | $14.5M | +20.5% |
| FY2023 | $12.0M | -22.7% |
| FY2022 | $15.6M | -9.0% |
| FY2021 | $17.1M | +22.1% |
| FY2020 | $14.0M | +28.8% |
| FY2019 | $10.9M | -72.9% |
| FY2018 | $40.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026